Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA RCC-208 study of pumitamig alone or with ipilimumab or cabozantinib in advanced renal cell carcinoma
2026-527163-15-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of pumitamig in renal cell carcinoma (RCC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability and Objective response rate. Planned start Sep 2026; status: authorised.
02
Drugs
pumitamig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2026-527163-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527163-15-00.